Engineering CAR T cells to secrete and deliver high concentrations of human mAbs against molecules involved in immune checkpoint blockade at the tumor site could diminish their potential to become exhausted as well as lead to trans reversal of exhaustion for the CD8+TILs and other immune cells that have accumulated at the tumor site. This evidence concerns the gene CD8A and neoplasm.